MaxCyte, Inc. (NASDAQ:MXCT – Get Free Report) Director Stanley C. Erck sold 21,607 shares of the company’s stock in a transaction dated Wednesday, October 2nd. The shares were sold at an average price of $3.71, for a total value of $80,161.97. Following the transaction, the director now directly owns 269,118 shares in the company, valued at $998,427.78. The sale was disclosed in a filing with the SEC, which is available through this link.
MaxCyte Stock Performance
Shares of MXCT traded up $0.04 during trading hours on Wednesday, hitting $3.74. The stock had a trading volume of 410,809 shares, compared to its average volume of 532,271. MaxCyte, Inc. has a fifty-two week low of $2.45 and a fifty-two week high of $5.55. The firm has a 50-day moving average price of $4.17 and a 200 day moving average price of $4.26. The firm has a market capitalization of $392.04 million, a price-to-earnings ratio of -10.57 and a beta of 1.40.
MaxCyte (NASDAQ:MXCT – Get Free Report) last posted its quarterly earnings data on Tuesday, August 6th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.05. The firm had revenue of $10.43 million for the quarter, compared to the consensus estimate of $8.20 million. MaxCyte had a negative return on equity of 15.52% and a negative net margin of 77.97%. During the same quarter in the previous year, the business earned ($0.10) EPS. As a group, analysts predict that MaxCyte, Inc. will post -0.44 EPS for the current fiscal year.
Institutional Trading of MaxCyte
About MaxCyte
MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.
Featured Stories
- Five stocks we like better than MaxCyte
- Top Biotech Stocks: Exploring Innovation Opportunities
- S&P 500 Hitting Resistance: These 3 Stocks Offer the Best Upside
- Stock Sentiment Analysis: How it Works
- Nike’s Post-Earnings Drop Presents a Buying Opportunity
- What is the Shanghai Stock Exchange Composite Index?
- Microsoft’s Targeted Upside Might Be Too Good to Ignore
Receive News & Ratings for MaxCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MaxCyte and related companies with MarketBeat.com's FREE daily email newsletter.